A Pediatric Primer on Influenza: Insights and Interventions
Influenza places a substantial burden on the health of people in the United States each year, with varying impact. The Centers for Disease Control and Prevention estimates that influenza has resulted in between 9 million and 45 million illnesses, between 140,000 and 810,000 hospitalizations, and between 12,000 and 61,000 deaths annually since 2010. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Pediatric and family practice physicians and other clinicians who evaluate patients must keep apprised of new data regarding the diagnosis and treatment of influenza so they can better identify and help manage influenza in the community, reducing patient morbidity and mortality. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes (although adamantanes are not recommended for use in the United States), and the polymerase inhibitor baloxavir marboxil. This CME/AANP program “Pediatric Primer on Influenza: Insights and Interventions” will utilize the ArcheMedX Intelligent Learning Platform and explore the burden of pediatric influenza. Experts will review best practices for diagnosis as well as selection of the most appropriate treatment in children and adolescents with influenza based on its safety, efficacy, and ability to reduce complications in patients at normal or at high risk.
Cost: FreeView Offer chevron_right
Free; 1.25 AMA PRA Category 1 Credit(s)™; up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program; The My Healio CME Dashboard keeps track of earned credits and saved activities; Personalized recommendations make finding your next activity easy; Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
Influenza; Flu; Centers of Disease Control and Prevention; CDC; Antiviral treatment; Fever; Neuraminidase inhibitors; Adamantanes; Polymerase inhibitor baloxavir marboxil
Upon successful completion of this activity, participants should be better able to: -Summarize the burden of influenza in the pediatric population, as well as evidence-based recommendations regarding its diagnosis. -Evaluate new evidence regarding the use of antivirals for the treatment of pediatric and adolescent influenza. -Utilize antiviral therapy in pediatric and adolescent patients to improve outcomes in those who are at normal or high risk for influenza complications.
The intended audience for this activity is pediatricians, family practice physicians, pediatric nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Additional credit info
Provider Statement This continuing medical education activity is provided by Vindico Medical Education. Support Statement This activity is supported by an educational grant from Genentech, Inc. Accreditation Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. Participants who successfully complete the program and opt-in by providing their ABP ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20104581. This activity was planned in accordance with AANP Accreditation Standards and Policies. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program. This enduring material is approved for 1 year from the date of original release, November 30, 2020 to November 29, 2021.